The Prevalence of Diagnosed Opioid Abuse in Commercial and Medicare Managed Care Populations. Issue 3 (1st December 2013)

• Record Type: Journal Article
• Authors: Dufour, Robert; Joshi, Ashish V.; Pasquale, Margaret K.; Schaaf, David; Mardekian, Jack; Andrews, George A.; Patel, Nick C.
• Is Part Of: Pain practice. Volume 14:Issue 3(2014)
• Page Start: E106
• Page End: E115
• Publication Date: 2013-12-01
• Subjects: Pain -- Treatment -- Periodicals; 616.0472
• DOI: 10.1111/papr.12148
• Languages: English
• ISSNs: 1530-7085

Abstract

<abstract abstract-type="main" id="papr12148-abs-0001"> <title>Abstract</title> <sec id="papr12148-sec-0001" sec-type="section"> <title>Purpose</title> <p>To measure the prevalence of diagnosed opioid abuse and prescription opioid use in a multistate managed care organization.</p> </sec> <sec id="papr12148-sec-0002" sec-type="section"> <title>Methods</title> <p>This retrospective claims data analysis reviewed the prevalence of diagnosed opioid abuse and the parallel prevalence of prescription opioid use in half‐year intervals for commercial and Medicare members enrolled with Humana Inc., from January 1, 2008 to June 30, 2010. Diagnosis of opioid abuse was defined by ≥ 1 medical claim with any of the following ICD‐9‐CM codes: 304.0 ×, 304.7 ×, 305.5 ×, 965.0 ×, excluding 965.01, and opioid use was defined by ≥ 1 filled prescription for an opioid. The prevalence of opioid abuse was defined by the number of members with an opioid abuse diagnosis, divided by the number of members enrolled in each 6‐month interval.</p> </sec> <sec id="papr12148-sec-0003" sec-type="section"> <title>Results</title> <p>The 6‐month prevalence of diagnosed opioid abuse increased from 0.84 to 1.15 among commercial and from 3.17 to 6.35 among Medicare members, per 1, 000. In contrast, there was no marked increase in prescription opioid use during the same time period (118.0 to 114.8 for commercial members, 240.6 to 256.9 for Medicare members, per 1, 000). The prevalence of diagnosed opioid abuse was highest among members younger than 65 years for both genders in commercial (18‐ to 34‐year‐olds) and Medicare (35‐ to 54‐year‐olds) populations.</p> </sec> <sec id="papr12148-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Despite a stable rate of prescription opioid use among the observed population, the prevalence of diagnosed opioid abuse is increasing, particularly in the Medicare population.</p> </sec> </abstract>